Current Hematologic Malignancy Reports

, Volume 6, Issue 3, pp 172–179

The Role of Autologous Transplantation in Hodgkin Lymphoma



Between 80% and 90% of Hodgkin lymphoma (HL) patients can be cured with up-to-date combined-modality treatments, but patients with disease refractory to first-line therapy and those who relapse after first-line therapy still have a relatively poor prognosis. Dose intensification with stem cell support has been evaluated both to avoid relapses and to cure patients with refractory or relapsed disease. In this review, we focus on the use of high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) in first-line, second-line, and third-line therapy for HL patients. The relevance of salvage therapy before high-dose chemotherapy is discussed, as well as the role of sequential high dose chemotherapy. We also review current evidence for tandem transplantation in high-risk HL patients and ASCT in elderly patients. Finally, we discuss current concepts of ASCT for HL patients and the use of functional imaging and consolidation therapy.


Hodgkin lymphoma HL Autologous stem cell transplantation ASCT Tandem transplantation Stem cell transplant High-dose chemotherapy Consolidation Maintenance Salvage 


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Engert A, Plutschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. N Engl J Med. 2010;363:640–52.PubMedCrossRefGoogle Scholar
  2. 2.
    Eich HT, Diehl V, Gorgen H, et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol. 2010;28:4199–206.PubMedCrossRefGoogle Scholar
  3. 3.
    Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease. N Engl J Med. 2003;348:2386–95.PubMedCrossRefGoogle Scholar
  4. 4.
    Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992;327:1478–84.PubMedCrossRefGoogle Scholar
  5. 5.
    Engert A, Diehl V, Franklin J, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin’s lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol. 2009;27:4548–54.PubMedCrossRefGoogle Scholar
  6. 6.
    Fleury J, Legros M, Colombat P, et al. High-dose therapy and autologous bone marrow transplantation in first complete or partial remission for poor prognosis Hodgkin’s disease. Leuk Lymphoma. 1996;20:259–66.PubMedCrossRefGoogle Scholar
  7. 7.
    Gianni AM, Siena S, Bregni M, et al. Prolonged disease-free survival after high-dose sequential chemo-radiotherapy and haemopoietic autologous transplantation in poor prognosis Hodgkin’s disease. Ann Oncol. 1991;2:645–53.PubMedGoogle Scholar
  8. 8.
    Carella AM, Pollicardo N, Pungolino E, et al. Autologous stem cell transplantation as adjuvant treatment vs no further therapy for poor-risk Hodgkin’s disease in first complete remission after MOPP/ABVD. Leuk Lymphoma 15 Suppl 1:59–61, 1995.Google Scholar
  9. 9.
    Arakelyan N, Berthou C, Desablens B, et al. Early versus late intensification for patients with high-risk Hodgkin lymphoma—3 cycles of intensive chemotherapy plus low-dose lymph node radiation therapy versus 4 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine plus myeloablative chemotherapy with autologous stem cell transplantation: five-year results of a randomized trial on behalf of the GOELAMS Group. Cancer. 2008;113:3323–30.PubMedCrossRefGoogle Scholar
  10. 10.
    Federico M, Bellei M, Brice P, et al. High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin’s lymphoma responding to front-line therapy. J Clin Oncol. 2003;21:2320–5.PubMedCrossRefGoogle Scholar
  11. 11.
    • Carella AM, Bellei M, Brice P, et al. High-dose therapy and autologous stem cell transplantation versus conventional therapy for patients with advanced Hodgkin’s lymphoma responding to front-line therapy: long-term results. Haematologica 94:146–8, 2009. A long-term update of the randomized HD01 trial, which compared four additional cycles of conventional anthracycline-containing chemotherapy with high-dose chemotherapy and stem cell transplantation as consolidation for high-risk HL. The results demonstrated that patients responding to initial conventional chemotherapy should not be treated with high-dose chemotherapy as consolidation. Google Scholar
  12. 12.
    Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomised trial. Lancet. 1993;341:1051–4.PubMedCrossRefGoogle Scholar
  13. 13.
    Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet. 2002;359:2065–71.PubMedCrossRefGoogle Scholar
  14. 14.
    Josting A, Franklin J, May M, et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin’s lymphoma registered in the database of the German Hodgkin’s Lymphoma Study Group. J Clin Oncol. 2002;20:221–30.PubMedCrossRefGoogle Scholar
  15. 15.
    Chopra R, McMillan AK, Linch DC, et al. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin’s disease. A single-center eight-year study of 155 patients. Blood. 1993;81:1137–45.PubMedGoogle Scholar
  16. 16.
    Crump M, Smith AM, Brandwein J, et al. High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin’s disease: importance of disease status at transplant. J Clin Oncol. 1993;11:704–11.PubMedGoogle Scholar
  17. 17.
    Gribben JG, Linch DC, Singer CR, et al. Successful treatment of refractory Hodgkin’s disease by high-dose combination chemotherapy and autologous bone marrow transplantation. Blood. 1989;73:340–4.PubMedGoogle Scholar
  18. 18.
    Josting A, Katay I, Rueffer U, et al. Favorable outcome of patients with relapsed or refractory Hodgkin’s disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dex-BEAM). Ann Oncol. 1998;9:289–95.PubMedCrossRefGoogle Scholar
  19. 19.
    Rapoport AP, Rowe JM, Kouides PA, et al. One hundred autotransplants for relapsed or refractory Hodgkin’s disease and lymphoma: value of pretransplant disease status for predicting outcome. J Clin Oncol. 1993;11:2351–61.PubMedGoogle Scholar
  20. 20.
    Diehl V, Franklin J, Hasenclever D, et al. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin’s lymphoma: interim report from a trial of the German Hodgkin’s Lymphoma Study Group. J Clin Oncol. 1998;16:3810–21.PubMedGoogle Scholar
  21. 21.
    Josting A, Rudolph C, Reiser M, et al. Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin’s disease. Ann Oncol. 2002;13:1628–35.PubMedCrossRefGoogle Scholar
  22. 22.
    Colwill R, Crump M, Couture F, et al. Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin’s disease before intensive therapy and autologous bone marrow transplantation. J Clin Oncol. 1995;13:396–402.PubMedGoogle Scholar
  23. 23.
    Sibon D, Ertault M, Al Nawakil C, et al. Combined ifosfamide, etoposide and oxaliplatin chemotherapy, a low-toxicity regimen for first-relapsed or refractory Hodgkin lymphoma after ABVD/EBVP: a prospective monocentre study on 34 patients. Br J Haematol 2011 Mar 8 (Epub ahead of print).Google Scholar
  24. 24.
    Santoro A, Magagnoli M, Spina M, et al. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin’s lymphoma. Haematologica. 2007;92:35–41.PubMedCrossRefGoogle Scholar
  25. 25.
    Todd T, Raj S, Camilleri D, et al. Intermediate dose gemcitabine-cisplatin combination chemotherapy without treatment delay for cytopenia followed by autografting–a new standard of care in relapsed or refractory Hodgkin lymphoma? Ann Hematol. 2009;88:1107–12.PubMedCrossRefGoogle Scholar
  26. 26.
    Moskowitz CH, Yahalom J, Zelenetz AD, et al. High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging. Br J Haematol. 2010;148:890–7.PubMedCrossRefGoogle Scholar
  27. 27.
    Kuruvilla J, Keating A, Crump M: How I treat relapsed and refractory Hodgkin lymphoma. Blood. 2011 Jan 24 (Epub ahead of print).Google Scholar
  28. 28.
    Brandwein JM, Callum J, Sutcliffe SB, et al. Evaluation of cytoreductive therapy prior to high dose treatment with autologous bone marrow transplantation in relapsed and refractory Hodgkin’s disease. Bone Marrow Transplant. 1990;5:99–103.PubMedGoogle Scholar
  29. 29.
    Stewart AK, Brandwein JM, Sutcliffe SB, et al. Mini-beam as salvage chemotherapy for refractory Hodgkin’s disease and non-Hodgkin’s lymphoma. Leuk Lymphoma. 1991;5:111–5.PubMedCrossRefGoogle Scholar
  30. 30.
    Magyari F, Simon Z, Miltényi Z, et al. Successful rituximab-bendamustine treatment in progression of Hodgkin Lymphoma after autologous hematopoietic stem cell transplant (auto-HSCT). Haematologica. 2010;95:29.Google Scholar
  31. 31.
    Norton L, Simon R. The Norton-Simon hypothesis revisited. Cancer Treat Rep. 1986;70:163–9.PubMedGoogle Scholar
  32. 32.
    Josting A, Rudolph C, Mapara M, et al. Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG). Ann Oncol. 2005;16:116–23.PubMedCrossRefGoogle Scholar
  33. 33.
    •• Josting A, Müller H, Borchmann P, et al. Dose intensity of chemotherapy in patients with relapsed Hodgkin’s lymphoma. J Clin Oncol 28:5074–80, 2010. The HD-R2 trial, which was the largest randomized trial ever performed in relapsed HL, showed that patients do not benefit from sequential high-dose therapy before myeloablative high-dose chemotherapy. It demonstrated excellent results with a combination of time-intensified DHAP and BEAM as salvage/conditioning regimens, as compared with historical data. Google Scholar
  34. 34.
    Fung HC, Stiff P, Schriber J, et al. Tandem autologous stem cell transplantation for patients with primary refractory or poor risk recurrent Hodgkin lymphoma. Biol Blood Marrow Transplant. 2007;13:594–600.PubMedCrossRefGoogle Scholar
  35. 35.
    •• Morschhauser F, Brice P, Ferme C, et al. Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin’s lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study group. J Clin Oncol 26:5980–7, 2008. This prospective trial tested tandem transplantation as a strategy for treating patients with high-risk relapsed/refractory HL. Results compared favorably with historical data, especially in high-risk patients not achieving a complete remission after salvage therapy. Google Scholar
  36. 36.
    Sureda A, Robinson S, Canals C, et al. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin’s lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2008;26:455–62.PubMedCrossRefGoogle Scholar
  37. 37.
    Smith SM, van Besien K, Carreras J, et al. Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant. Biol Blood Marrow Transplant. 2008;14:904–12.PubMedCrossRefGoogle Scholar
  38. 38.
    Puig N, Pintilie M, Seshadri T, et al. High-dose chemotherapy and ASCT in elderly patients with Hodgkin’s lymphoma. Bone Marrow Transplant. 2011 Jan 17 (Epub ahead of print).Google Scholar
  39. 39.
    Sureda A, Younes A, Ben-Yehuda D, et al. Final analysis: Phase II study of oral panobinostat in relapsed/refractory Hodgkin lymphoma patients following autologous hematopoietic stem cell transplant [abstract]. ASH Annual Meeting Abstracts. 2010;116:419.Google Scholar
  40. 40.
    Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363:1812–21.PubMedCrossRefGoogle Scholar
  41. 41.
    Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood. 2006;107:52–9.PubMedCrossRefGoogle Scholar
  42. 42.
    Kobe C, Dietlein M, Franklin J, et al. Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. Blood. 2008;112:3989–94.PubMedCrossRefGoogle Scholar
  43. 43.
    Crocchiolo R, Canevari C, Assanelli A, et al. Pre-transplant 18FDG-PET predicts outcome in lymphoma patients treated with high-dose sequential chemotherapy followed by autologous stem cell transplantation. Leuk Lymphoma. 2008;49:727–33.PubMedCrossRefGoogle Scholar
  44. 44.
    Jabbour E, Hosing C, Ayers G, et al. Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma. Cancer. 2007;109:2481–9.PubMedCrossRefGoogle Scholar
  45. 45.
    Moskowitz AJ, Yahalom J, Kewalramani T, et al. Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Blood. 2010;116:4934–7.PubMedCrossRefGoogle Scholar
  46. 46.
    Castagna L, Bramanti S, Balzarotti M, et al. Predictive value of early 18 F-fluorodeoxyglucose positron emission tomography (FDG-PET) during salvage chemotherapy in relapsing/refractory Hodgkin lymphoma (HL) treated with high-dose chemotherapy. Br J Haematol. 2009;145:369–72.PubMedCrossRefGoogle Scholar
  47. 47.
    Schot BW, Zijlstra JM, Sluiter WJ, et al. Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma. Blood. 2007;109:486–91.PubMedCrossRefGoogle Scholar
  48. 48.
    Johnston PB, Inwards DJ, Colgan JP, et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol. 2010;85:320–4.PubMedGoogle Scholar
  49. 49.
    Rodriguez J, Rodriguez MA, Fayad L, et al. ASHAP: a regimen for cytoreduction of refractory or recurrent Hodgkin’s disease. Blood. 1999;93:3632–6.PubMedGoogle Scholar
  50. 50.
    Zinzani PL, Barbieri E, Bendandi M, et al. CEP regimen (CCNU, etoposide, prednimustine) for relapsed/refractory Hodgkin’s disease. Tumori. 1994;80:438–42.PubMedGoogle Scholar
  51. 51.
    Pfreundschuh MG, Rueffer U, Lathan B, et al. Dexa-BEAM in patients with Hodgkin’s disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin’s Disease Study Group. J Clin Oncol. 1994;12:580–6.PubMedGoogle Scholar
  52. 52.
    Aparicio J, Segura A, Garcera S, et al. ESHAP is an active regimen for relapsing Hodgkin’s disease. Ann Oncol. 1999;10:593–5.PubMedCrossRefGoogle Scholar
  53. 53.
    Baetz T, Belch A, Couban S, et al. Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin’s disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol. 2003;14:1762–7.PubMedCrossRefGoogle Scholar
  54. 54.
    Bartlett NL, Niedzwiecki D, Johnson JL, et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin’s lymphoma: CALGB 59804. Ann Oncol. 2007;18:1071–9.PubMedCrossRefGoogle Scholar
  55. 55.
    Moskowitz CH, Nimer SD, Zelenetz AD, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood. 2001;97:616–23.PubMedCrossRefGoogle Scholar
  56. 56.
    Bonfante V, Viviani S, Santoro A, et al. Ifosfamide and vinorelbine: an active regimen for patients with relapsed or refractory Hodgkin’s disease. Br J Haematol. 1998;103:533–5.PubMedCrossRefGoogle Scholar
  57. 57.
    Hagemeister FB, Tannir N, McLaughlin P, et al. MIME chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) as treatment for recurrent Hodgkin’s disease. J Clin Oncol. 1987;5:556–61.PubMedGoogle Scholar
  58. 58.
    Ferme C, Bastion Y, Lepage E, et al. The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin’s disease. Ann Oncol. 1995;6:543–9.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Department of Internal Medicine ICologne University HospitalCologneGermany

Personalised recommendations